---
title: "Fennec Pharmaceuticals (TSE:FRX) Director Purchases C$15,578.42 in Stock"
description: "Fennec Pharmaceuticals (TSE:FRX) Director Rostislav Christov Raykov purchased 4,609 shares at C$3.38 each, totaling C$15,578.42, increasing his ownership by 0.17%. Following this, he holds 2,697,927 s"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260737634.md"
published_at: "2025-10-11T10:21:49.000Z"
---

# Fennec Pharmaceuticals (TSE:FRX) Director Purchases C$15,578.42 in Stock

> Fennec Pharmaceuticals (TSE:FRX) Director Rostislav Christov Raykov purchased 4,609 shares at C$3.38 each, totaling C$15,578.42, increasing his ownership by 0.17%. Following this, he holds 2,697,927 shares valued at approximately C$9.12 million. Meanwhile, Southpoint Capital Advisors sold 19,605 shares for C$256,237.35. The stock has declined by 7.4%, currently trading at C$12.30, with a 12-month range of C$5.65 to C$13.83. Fennec focuses on developing Sodium Thiosulfate to prevent chemotherapy-induced hearing loss in children.

## Key Points

-   **Southpoint Capital Advisors Lp** sold 19,605 shares of Fennec Pharmaceuticals, amounting to a total of C$256,237.35 at an average price of C$13.07 per share.
-   The stock price of **Fennec Pharmaceuticals** has declined by 7.4%, with a current trading price of C$12.30.
-   Fennec Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments such as **Sodium Thiosulfate** to prevent hearing loss in children undergoing chemotherapy.

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Rostislav Christov Raykov purchased 4,609 shares of the business's stock in a transaction that occurred on Wednesday, October 8th. The stock was acquired at an average price of C$3.38 per share, for a total transaction of C$15,578.42. Following the acquisition, the director owned 2,697,927 shares in the company, valued at C$9,118,993.26. This trade represents a 0.17% increase in their position.

## Fennec Pharmaceuticals Price Performance

Shares of TSE:FRX opened at C$12.30 on Friday. Fennec Pharmaceuticals Inc. has a twelve month low of C$5.65 and a twelve month high of C$13.83. The company's 50 day moving average is C$12.20 and its 200 day moving average is C$10.73. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The company has a market cap of C$342.33 million, a PE ratio of -27.33 and a beta of 2.48.

## Fennec Pharmaceuticals Company Profile

(Get Free Report)

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

## Recommended Stories

-   Five stocks we like better than Fennec Pharmaceuticals
-   Investing In Preferred Stock vs. Common Stock
-   3 Heavily Shorted Stocks That Could Pop on Rate Cuts
-   Large Cap Stock Definition and How to Invest
-   Broadcom Gets Second $420 Target as CPO Win Boosts Outlook
-   Are Penny Stocks a Good Fit for Your Portfolio?
-   PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can

*This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to \[email protected\].*

Insider Buying or Selling at Fennec Pharmaceuticals?

Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Fennec Pharmaceuticals and related companies.

From Our Partners

Bitcoin grabs headlines, but smart money likes this token

Bitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...

Crypto 101 MediaCapital Gains Tax Strategies for Seniors

Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...

SmartAssetINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off

Right now, we’re witnessing a monumental shift in the world.

Traders AgencyAn $8 trillion-dollar discovery 17,000 ft underwater

A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...

Porter & Company2013 miner reveals his trading system

While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...

Crypto Swap ProfitsClaim Your Share of $5.39 BILLION in AI Equity Checks

The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...

Angel PublishingForget AI, This Will Be the Next Big Tech Breakthrough

After picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...

Brownstone ResearchURGENT: The Market's 3 Red Flags Are Flashing

Here’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...

StockEarnings

### Related Stocks

- [FENC.US - Fennec Pharma](https://longbridge.com/en/quote/FENC.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Fennec Pharmaceuticals Director Rosty Raykov Reports Disposal of Common Shares | Rosty Raykov, a Director at Fennec Pharmaceuticals Inc., has reported the disposal of common shares of the company. The  | [Link](https://longbridge.com/en/news/274562415.md) |
| 3 'Strong Buy' Stocks to Buy Now, 2/12/2026, According to Top Analysts | Top Wall Street Analysts recommend three stocks as 'Strong Buys': Fennec Pharmaceuticals (FENC) with a price target of $ | [Link](https://longbridge.com/en/news/275777502.md) |
| TC Energy beats fourth-quarter profit estimates | Feb 13 (Reuters) - Canadian pipeline operator TC Energy (TRP.TO) beat analysts’ estimates for fourth-quarter adjusted pr | [Link](https://longbridge.com/en/news/275892649.md) |
| Medexus Pharmaceuticals reports Q3 results | Medexus Pharmaceuticals reports Q3 results | [Link](https://longbridge.com/en/news/275670725.md) |
| Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Savant Capital LLC | Savant Capital LLC reduced its stake in Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) by 50.7% in Q3, now holding 48,886  | [Link](https://longbridge.com/en/news/275591859.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
